Medical Research News

Nursing

sponsor

Your Unread Messages

Hello, Mary O'connor
Manage E-mail  |  Logout
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Blonde L et al. – Liraglutide is a new glucagon–like peptide–1 (GLP–1) receptor agonist and a true GLP–1 analogue. After successful phase 2 studies, liraglutide was assessed in a series of phase 3 trials. Liraglutide was associated with a low risk of hypoglycaemia and was generally well tolerated. The majority of adverse effects were gastrointestinal, the most frequent of which was nausea.

Related Articles

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09    Relevance Score: 97%

Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09    Relevance Score: 97%

A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Pharmacotherapy, 10/28/09    Relevance Score: 97%

Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09    Relevance Score: 97%

Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09    Relevance Score: 97%

Today in Clinical Pharmacology...keeping you current

Serum Thyroid-Stimulating Hormone Concentration and Morbidity from Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy
Journal of Clinical Endocrinology and Metabolism, 11/24/09

Adult Cyclic Vomiting Syndrome Successfully Treated with Intranasal Sumatriptan
Journal of General Internal Medicine, 11/24/09

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review
Journal of Cystic Fibrosis , 11/24/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address